

## Appendix 9

### Notification of an outcome of the national registration provided by the participating manufacturer to the World Health Organization

#### Details of pharmaceutical manufacturer using the Procedure<sup>1</sup>

Manufacturer: . \_\_\_\_\_  
 Country: . \_\_\_\_\_  
 Address: . \_\_\_\_\_  
 Focal point: . \_\_\_\_\_  
 Telephone number (please include codes): . \_\_\_\_\_  
 Email: . \_\_\_\_\_

#### Details of pharmaceutical product or vaccine (the Product) subject to the Procedure

Name of the Product: . \_\_\_\_\_  
 Active pharmaceutical ingredient (s): . \_\_\_\_\_  
 Strength: . \_\_\_\_\_  
 Dosage form: . \_\_\_\_\_

#### Course of the Procedure

Country: . \_\_\_\_\_  
 Regulatory authority: . \_\_\_\_\_  
 Date of submission of the application: . \_\_\_\_\_  
 Date of acceptance of the application (if different from submission date): . \_\_\_\_\_  
 Date of issuance of a decision: . \_\_\_\_\_  
 Length of process interruption/clock-stop (if applicable):<sup>2</sup> . \_\_\_\_\_

<sup>1</sup> Collaborative procedure in assessment and accelerated national registration of pharmaceutical products and vaccines approved by stringent regulatory authorities – facilitated by WHO.

<sup>2</sup> Time provided by NRA to the applicant to complete data or respond to regulatory questions.

## Decision on registration

Granted, rejected, withdrawn: . \_\_\_\_\_

Registration number (if applicable): . \_\_\_\_\_

Registration granted in line with the reference SRA decision or with deviations, please comment: . \_\_\_\_\_

## Compliance with the Procedure, other observations and recommendations

In the course of the Procedure the following deviations were observed and recorded: . \_\_\_\_\_

Any other observations and recommendations: . \_\_\_\_\_

\_\_\_\_\_

For the manufacturer

Signature: \_\_\_\_\_

Name: . \_\_\_\_\_

Title: . \_\_\_\_\_

Place and date: . \_\_\_\_\_

